Sarah Cannon Research Institute, LLC (Sarah Cannon) is an oncology-focused clinical research organization and research network headquartered in Nashville, Tennessee, and affiliated with HCA Healthcare. The institute designs and conducts Phase I–III trials across solid tumors and hematologic malignancies, supporting first-in-human studies and multicenter development programs in collaboration with biopharmaceutical companies.
Sarah Cannon provides capabilities in protocol design, site management, regulatory oversight, data management, and translational research, including biomarker-driven and precision medicine studies. Its investigator and patient network spans the United States and the United Kingdom, working with community and academic sites to expand access to experimental therapies and generate clinical evidence that informs cancer drug development.
None yet. When a new project in the record names Sarah Cannon as owner, partner or investor, it shows here.
Rina-S shows 50% response rate in advanced endometrial cancer trial; FDA grants Breakthrough Therapy Designation.
